RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Series X Capital
S

Series X Capital portfolio

Series X Capital has 2 portfolio companies on record at Recent Funding, with 1 investment in the last 12 months.

Website: seriesx.capital.
Type: Venture capital.
Portfolio on Recent Funding: 2.
Deals, last 12 months: 1.
Rounds led: 1 of 1.
Capital in their rounds: $300M.
Latest deal: Verily · Mar 19, 2026.
About this page

It is a venture capital firm based in San Francisco, US. Its most recent investment on record is Verily's $300M Series B+ round in March 2026, which it led, alongside Alphabet, University of Colorado Anschutz and UCHealth. By category, its portfolio leans toward Health and bio (1) and Data and analytics (1).

About Series X Capital

Firm type: Venture capital.
Headquarters: San Francisco, US.
Stages: Seed, Series A.
Sectors: AI & Machine Learning, Deep Tech, Digital Health, Healthtech, Logistics & Supply Chain, PropTech.
Portfolio companies: 5.
Exits: 0.
Rounds led: 0.

What Series X Capital invests in

How Series X Capital invests

StageDealsCapital in rounds
Series B+ 1 100%$300M

Series X Capital portfolio companies

CompanyRound with Series X CapitalTotal raisedLatest raise
VVerily
Health and bio
Series B+ · $300M · lead$3BMar 19, 2026
Series B+
TTaara
Manufacturing and industrial
backer · sourceundisclosed—

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 1 round on Recent Funding that name Series X Capital. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Series X Capital, which is a subset of its real portfolio. API: /api/v1/investors/series-x-capital (get a free API key). More: the most active VC firms and new venture capital funds.